STIM
Neuronetics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.67
P/S
0.71
EV/EBITDA
-5.77
DCF Value
$-54.37
FCF Yield
-20.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
48.5%
Operating Margin
-21.1%
Net Margin
-26.1%
ROE
-138.9%
ROA
-39.1%
ROIC
-27.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $41.8M | $-7.2M | $-0.10 |
| FY 2025 | $149.2M | $-39.0M | $-0.59 |
| Q3 2025 | $37.3M | $-9.0M | $-0.13 |
| Q2 2025 | $38.1M | $-10.1M | $-0.15 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.87
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.